BIOMARIN PHARMACEUTICAL INC
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) is a global rare disease biotechnology company headquartered in San Rafael, California. The company focuses on delivering medicines for people living with genetically defined conditions, leveraging distinctive approaches to drug discovery and development that target the root… From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What BIOMARIN PHARMACEUTICAL INC does
In the company’s own words
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) is a global rare disease biotechnology company headquartered in San Rafael, California. The company focuses on delivering medicines for people living with genetically defined conditions, leveraging distinctive approaches to drug discovery and development that target the root causes of genetic disorders with significant unmet medical needs.
The company operates through two primary business units: Skeletal Conditions and Enzyme Therapies. BioMarin's commercial portfolio includes eight approved therapies addressing various rare genetic diseases. VOXZOGO, a once-daily injection for achondroplasia, generated $926.9 million in 2025 revenues and represents the company's flagship skeletal conditions product. The enzyme therapies segment includes VIMIZIM for mucopolysaccharidosis IVA, NAGLAZYME for MPS VI, PALYNZIQ for phenylketonuria, ALDURAZYME for MPS I, BRINEURA for neuronal ceroid lipofuscinosis type 2, and KUVAN for PKU, collectively generating approximately $2.0 billion in 2025 revenues. ROCTAVIAN, a gene therapy for severe hemophilia A, contributed $35.6 million before the company committed to voluntary market withdrawal in December 2025.
BioMarin achieved total revenues of $3.2 billion in 2025. The company maintains manufacturing facilities in Novato, California and Shanbally, Cork, Ireland, with additional contract manufacturing relationships supporting production of active pharmaceutical ingredients and drug products. The company's research and development pipeline includes multiple clinical and preclinical candidates, including BMN 333 for growth disorders, BMN 351 for Duchenne Muscular Dystrophy, and BMN 401 for ENPP1 deficiency, acquired through the Inozyme acquisition completed in July 2025.
In December 2025, BioMarin entered into a definitive agreement to acquire Amicus Therapeutics for approximately $4.8 billion, expected to close in the second quarter of 2026. This acquisition is intended to strengthen the commercial portfolio by adding therapies for Fabry disease and late-onset Pompe disease. The company maintains a global commercial organization with direct sales operations in the U.S., Europe, South America and other significant markets, supported by distributor agreements in selected territories. BioMarin was founded in 1997 and maintains its website at www.biomarin.com.
Company details
- Sector
- Healthcare
- Industry
- Pharmaceutical Preparations
- Headquarters
- NOVATO, CA
- Fiscal year end
- December
- CIK
- 1048477
- SIC
- 2834
Financial performance, year by year
Fiscal 2013–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns BIOMARIN PHARMACEUTICAL INC — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · BIOMARIN PHARMACEUTICAL INC’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
BIOMARIN PHARMACEUTICAL INC’s bonds, as funds hold them
Funds report holding 3 issues of BIOMARIN PHARMACEUTICAL INC’s debt, $397.80M at market value — what funds hold, not the company’s total debt. Weighted-average coupon 4.87%, maturing 2027 to 2034.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do BIOMARIN PHARMACEUTICAL INC and its peers compare on margins and cash generation over ten years?”
- “Where did five years of BIOMARIN PHARMACEUTICAL INC's earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in BIOMARIN PHARMACEUTICAL INC's last four quarterly filings that the numbers alone won't show?”